Abstract
Background: Multiple sclerosis (MS) is an inflammatory demyelinating disease featured
with neuroinflammation, demyelination, and the loss of oligodendrocytes. Cognitive impairment and depression are common neuropsychiatric symptoms in MS
that are poorly managed with the present interventions.
Objective: This study aimed to investigate the effects of low field magnetic stimulation
(LFMS), a novel non-invasive neuromodulation technology, on cognitive impairment
and depressive symptoms associated with MS using a mouse model of demyelination.
Methods: C57BL female mice were fed with a 0.2% cuprizone diet for 12 weeks to
induce a chronic demyelinating model followed by 4 weeks of cuprizone withdrawal
with either sham or LFMS treatment.
Results: Improved cognition and depression-like behaviour and restored weight gain
were observed in mice with LFMS treatment. Immunohistochemical and immunoblotting
data showed enhanced myelin basic protein (MBP) and myelin oligodendrocyte
glycoprotein expressions (MOG) in the prefrontal cortex of mice with LFMS treatment,
supporting that myelin repair was promoted. LFMS also increased the protein
expression of mature oligodendrocyte biomarker glutathione-S-transferase (GST-π). In addition, expression of TGF-β and associated receptors were elevated with LFMS treatment, implicating this pathway in the response.
Conclusion: Results from the present study revealed LFMS to have neuroprotective
effects, suggesting that LFMS has potential therapeutic value for treating cognitive
impairment and depression related to demyelination disorders.
DOI：
10.1111/1440-1681.13490